ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Shares Climb 2.6% – What’s Next?

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) rose 2.6% on Wednesday. The company traded as high as $55.93 and last traded at $55.81. 20,231 shares traded hands during mid-day trading, a decline of 46% from the average session volume of 37,778 shares. The stock had previously closed at $54.37.

ALPS Medical Breakthroughs ETF Price Performance

The company’s 50-day moving average is $58.94 and its 200-day moving average is $57.07.

Institutional Trading of ALPS Medical Breakthroughs ETF

Large investors have recently bought and sold shares of the stock. Harbor Investment Advisory LLC acquired a new stake in shares of ALPS Medical Breakthroughs ETF in the 2nd quarter valued at $29,000. Fulcrum Equity Management acquired a new stake in shares of ALPS Medical Breakthroughs ETF during the 2nd quarter worth about $263,000. Rhodes Investment Advisors Inc. ADV acquired a new stake in shares of ALPS Medical Breakthroughs ETF during the 3rd quarter worth about $266,000. Independent Financial Group LLC bought a new position in ALPS Medical Breakthroughs ETF during the 1st quarter valued at about $283,000. Finally, Sowell Financial Services LLC bought a new position in ALPS Medical Breakthroughs ETF during the 3rd quarter valued at about $436,000.

About ALPS Medical Breakthroughs ETF

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.